AgomAb Therapeutics NV【AGMB】銘柄情報

AgomAb Therapeutics NV (AGMB) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

13.81

( 2.83% )

買値

5.22

売値

14.50

出来高

96,415

12.4989 日の範囲 14.06

8.75 52 週間の範囲 17.4528

時価総額

680.115M

前日終値

13.43

始値

12.82

時刻

13.81

最終取引時間

財務取引量

US$ 1,253,525

VWAP

13.0013

平均取引量 (3 か月)

US$ 138,953

発行済株式数

49,247,975

配当利回り

PER

-0.07

1 株当たり利益 (EPS)

-143.22

歳入

純利益

-62.55M

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor ... AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium. 詳細を表示

セクター

業界

ウェブサイト

www.agomab.com

本社

Antwerp, Belgium

設立

2026

AgomAb Therapeutics NV is listed in the sector of the ナスダック市場 with ticker AGMB. The last closing price for AgomAb Therapeutics NV was US$13.43. Over the last year, AgomAb Therapeutics NV shares have traded in a share price range of US$ 8.75 to US$ 17.4528.

AgomAb Therapeutics NV currently has 49,247,975 shares in issue. The market capitalisation of AgomAb Therapeutics NV is US$680.11 million. AgomAb Therapeutics NV has a price to earnings ratio (PE ratio) of -0.07.

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study...

Agomab Announces Results of Annual General Meeting

Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage...

Agomab to Participate in Upcoming Conferences

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage...

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from...

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	2.89	26.4652014652	10.92	14	10.625	118382	12.52036528	DR
4	2.43	21.3532513181	11.38	14	8.75	115986	10.91226771	DR
12	3.1	28.9449112979	10.71	14	8.75	119558	10.99418823	DR
26	-0.74	-5.08591065292	14.55	17.4528	8.75	139295	12.35371366	DR
52	-0.74	-5.08591065292	14.55	17.4528	8.75	139295	12.35371366	DR
156	-0.74	-5.08591065292	14.55	17.4528	8.75	139295	12.35371366	DR
260	-0.74	-5.08591065292	14.55	17.4528	8.75	139295	12.35371366	DR